Validations Queue
47,884 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 3 of 5, 500 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
47,884
Reviewed
13
Filtered
2,297
page 3 / 5
Showing on page
500
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.59 | FDA ANDA210273: MULTIPLE VITAMINS INJECTION ADULT (ALPHA-TOCOPHEROL ACETATE) — APOTEX | fda 2026-04-09 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.59 | FDA ANDA205035: TRANEXAMIC ACID (TRANEXAMIC ACID) — EUGIA PHARMA | fda 2026-04-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA211022: LENALIDOMIDE (LENALIDOMIDE) — APOTEX | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.59 | FDA ANDA210671: MULTIPLE VITAMINS INJECTION PEDIATRIC (ASCORBIC ACID) — APOTEX | fda 2026-04-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA219271: CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE) — HETERO LABS LIMITED | fda 2026-04-29 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA209348: LENALIDOMIDE (LENALIDOMIDE) — DR REDDYS | fda 2026-04-27 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.59 | FDA ANDA210386: CANAGLIFLOZIN (CANAGLIFLOZIN) — AUROBINDO PHARMA LTD | fda 2026-04-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA218417: DEXTROMETHORPHAN POLISTIREX (DEXTROMETHORPHAN POLISTIREX) — AUROBINDO PHARMA LTD | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA203364: MESNA (MESNA) — RISING | fda 2026-04-09 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA211563: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — ALKEM LABS LTD | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA207974: FINGOLIMOD HYDROCHLORIDE (FINGOLIMOD HYDROCHLORIDE) — ALEMBIC | fda 2026-04-24 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA214055: SELEXIPAG (SELEXIPAG) — RK PHARMA | fda 2026-04-16 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA214618: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA019901: ALTACE (RAMIPRIL) — KING PHARMS LLC | fda 2026-05-07 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA NDA212306: XPOVIO (SELINEXOR) — KARYOPHARM THERAPS | fda 2026-04-30 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA NDA021303: ADDERALL XR 10 (AMPHETAMINE ASPARTATE) — TAKEDA PHARMS USA | fda 2026-04-23 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA BLA761147: ENNUMO (PEGFILGRASTIM-PCCG) — ACCORD BIOPHARMA INC. | fda 2026-05-07 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.59 | FDA NDA019414: CARDIOGEN-82 (RUBIDIUM CHLORIDE RB-82) — BRACCO | fda 2026-05-13 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA211026: MACITENTAN (MACITENTAN) — SEASONS BIOTECH | fda 2026-05-19 | COD_TECH_001 A16/N2-class TSMC process availability materially supports 2027 AI accelerator ramps Codex Research Pack | Semis | 50% | |
| 0.59 | FDA ANDA216910: GLYCOPYRROLATE (GLYCOPYRROLATE) — QUAGEN | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA208045: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — AUROBINDO PHARMA LTD | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA021891: CHILDREN'S CLARITIN (LORATADINE) — BAYER HEALTHCARE LLC | fda 2026-05-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA208283: EPLERENONE (EPLERENONE) — BRECKENRIDGE | fda 2026-05-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA207947: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.59 | FDA ANDA220104: MIRTAZAPINE (MIRTAZAPINE) — MICRO LABS | fda 2026-05-19 | CMQ_035 HBM4 16-layer stack design (required for Vera Rubin) places unprecedented yield and capacity strain on global memory fabrication facilities. Jensen Huang / Morgan Stanley | Semis/Memory | 68% | |
| 0.59 | FDA ANDA211020: BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE) — GRAVITI PHARMS | fda 2026-05-29 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA208400: XATMEP (METHOTREXATE SODIUM) — AZURITY | fda 2026-05-27 | SEM_014 Nvidia's Arizona-based TSMC factory successfully fabricated cutting-edge semiconductors on US soil for first time in decades (October 2025). Jensen Huang | Manufacturing | 86% | |
| 0.59 | FDA ANDA201452: LENALIDOMIDE (LENALIDOMIDE) — ARROW INTL | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA219271: CYCLOPHOSPHAMIDE (CYCLOPHOSPHAMIDE) — HETERO LABS LIMITED | fda 2026-04-29 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA079162: TOPIRAMATE (TOPIRAMATE) — INVAGEN PHARMS | fda 2026-04-24 | 232_036 AI drug deployment is very hard to launch in US due to human trials; easy in UAE. Ben Horowitz | Biotech/Longevity | 46% | |
| 0.59 | FDA ANDA207110: BOSENTAN (BOSENTAN) — WATSON LABS INC | fda 2026-04-14 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA090505: DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE) — IMPAX LABS INC | fda 2026-04-09 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.59 | FDA ANDA211537: DAPAGLIFLOZIN AND SAXAGLIPTIN HYDROCHLORIDE (DAPAGLIFLOZIN) — TORRENT | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA213267: THALIDOMIDE (THALIDOMIDE) — NATCO | fda 2026-04-24 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA220837: EVDI (TRABECTEDIN) — APOTEX | fda 2026-05-01 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA211182: ANDA211182 ((unspecified)) — HETERO LABS LTD V | fda 2026-04-16 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.59 | FDA ANDA090348: ZIPRASIDONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) — CHARTWELL RX | fda 2026-04-24 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA217180: JAKAFI XR (RUXOLITINIB PHOSPHATE) — INCYTE CORPORATION | fda 2026-05-01 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA ANDA208103: DEXMEDETOMIDINE HYDROCHLORIDE (DEXMEDETOMIDINE HYDROCHLORIDE) — BAXTER HLTHCARE CORP | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA BLA761328: BEYFORTUS (NIRSEVIMAB-ALIP) — ASTRAZENECA AB | fda 2026-04-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA216992: DEFLAZACORT (DEFLAZACORT) — UPSHER SMITH LABS | fda 2026-04-09 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA213929: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — LEADING | fda 2026-05-05 | CMQ_035 HBM4 16-layer stack design (required for Vera Rubin) places unprecedented yield and capacity strain on global memory fabrication facilities. Jensen Huang / Morgan Stanley | Semis/Memory | 68% | |
| 0.59 | FDA ANDA072736: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA NDA021488: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA NDA020515: ZOLADEX (GOSERELIN) — TERSERA | fda 2026-05-06 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.59 | FDA ANDA210236: POMALIDOMIDE (POMALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.59 | FDA ANDA218148: ATROPINE SULFATE (ATROPINE SULFATE) — MANKIND PHARMA | fda 2026-05-07 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA220421: ANDA220421 ((unspecified)) — HETERO LABS LIMITED, VEMAGAL | fda 2026-05-01 | 245_029 IVF will be transformed by Colossal's hydrogel/microfluidics embryo tech and new grading scale Ben Lamm | Biotech/Longevity | 41% | |
| 0.59 | FDA BLA761352: BIZENGRI (ZENOCUTUZUMAB-ZBCO) — MERUS N.V. | fda 2026-05-08 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA217761: SPIRONOLACTONE (SPIRONOLACTONE) — ANNORA PHARMA | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA219750: L-GLUTAMINE (L-GLUTAMINE) — STIRA | fda 2026-05-14 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA089534: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — SUN PHARM INDUSTRIES | fda 2026-05-12 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA BLA761452: IMMGOLIS (GOLIMUMAB-SLDI) — ACCORD BIOPHARMA INC. | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA BLA761468: HEPCLUDEX (BULEVIRTIDE-GMOD) — GILEAD SCIENCES INC | fda 2026-05-22 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.59 | FDA NDA219878: BAXFENDY (BAXDROSTAT) — ASTRAZENECA AB | fda 2026-05-15 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA220499: ANDA220499 ((unspecified)) — ALEMBIC PHARMACEUTICALS LIMITED | fda 2026-05-13 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.59 | FDA ANDA212975: IMATINIB MESYLATE (IMATINIB MESYLATE) — HETERO LABS LTD V | fda 2026-05-22 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA210215: AMANTADINE HYDROCHLORIDE (AMANTADINE HYDROCHLORIDE) — POM PHARMA | fda 2026-05-13 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.59 | FDA ANDA211255: LINACLOTIDE (LINACLOTIDE) — ACTAVIS LABS FL INC | fda 2026-05-19 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA081235: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — MYLAN | fda 2026-05-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA201749: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — SUN PHARM | fda 2026-05-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA BLA125166: SOLIRIS (ECULIZUMAB) — ALEXION PHARM | fda 2026-06-01 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA BLA022472: AFREZZA (INSULIN RECOMBINANT HUMAN) — MANNKIND | fda 2026-05-29 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA220043: VORICONAZOLE (VORICONAZOLE) — HAINAN POLY PHARM | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.59 | FDA ANDA216095: SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (MAGNESIUM SULFATE) — LUPIN | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.58 | FDA NDA021038: PRECEDEX (DEXMEDETOMIDINE HYDROCHLORIDE) — HOSPIRA | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA220033: ELTROMBOPAG OLAMINE (ELTROMBOPAG OLAMINE) — ZENARA | fda 2026-04-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA205071: MILNACIPRAN HYDROCHLORIDE (MILNACIPRAN HYDROCHLORIDE) — BRECKENRIDGE | fda 2026-04-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA216068: ENZALUTAMIDE (ENZALUTAMIDE) — SANDOZ | fda 2026-04-20 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA125504: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.58 | FDA ANDA216213: LENALIDOMIDE (LENALIDOMIDE) — AMNEAL | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA211547: DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (AMPHETAMINE ASPARTATE) — SPECGX LLC | fda 2026-04-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.58 | FDA NDA215430: AUVELITY (BUPROPION HYDROCHLORIDE) — AXSOME | fda 2026-04-30 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA216993: VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — DAIICHI SANKYO INC | fda 2026-04-29 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA761340: EPYSQLI (ECULIZUMAB-AAGH) — SAMSUNG BIOEPIS CO LTD | fda 2026-04-28 | CMQ_037 Samsung will grow global HBM market share from 20% to 28% by securing majority of orders for Vera Rubin-exclusive HBM4. Morgan Stanley | Semis/Memory | 29% | |
| 0.58 | FDA BLA761349: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA216579: SYMBICORT AEROSPHERE (BUDESONIDE) — ASTRAZENECA | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA213929: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — LEADING | fda 2026-05-05 | CMQ_037 Samsung will grow global HBM market share from 20% to 28% by securing majority of orders for Vera Rubin-exclusive HBM4. Morgan Stanley | Semis/Memory | 29% | |
| 0.58 | FDA ANDA090508: FINASTERIDE (FINASTERIDE) — SUN PHARM | fda 2026-04-30 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA091037: VALPROIC ACID (VALPROIC ACID) — SUN PHARM INDS LTD | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA022433: BRILINTA (TICAGRELOR) — ASTRAZENECA | fda 2026-05-07 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA NDA204819: ADEMPAS (RIOCIGUAT) — BAYER HLTHCARE | fda 2026-05-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA204345: CAPECITABINE (CAPECITABINE) — DR REDDYS | fda 2026-05-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA021379: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA091404: MEROPENEM (MEROPENEM) — ACS DOBFAR | fda 2026-05-20 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.58 | FDA ANDA215217: LEVALBUTEROL HYDROCHLORIDE (LEVALBUTEROL HYDROCHLORIDE) — NEPHRON | fda 2026-05-26 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA208028: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — INVAGEN PHARMS | fda 2026-05-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA761334: ZYNYZ (RETIFANLIMAB-DLWR) — INCYTE CORP | fda 2026-05-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA040054: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — HIKMA | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761354: TOFIDENCE (TOCILIZUMAB-BAVI) — BIOGEN MA | fda 2026-05-22 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA205081: MILNACIPRAN HYDROCHLORIDE (MILNACIPRAN HYDROCHLORIDE) — AMNEAL PHARMS | fda 2026-04-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA079162: TOPIRAMATE (TOPIRAMATE) — INVAGEN PHARMS | fda 2026-04-24 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA076781: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — HIKMA FARMACEUTICA | fda 2026-04-08 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA220221: VERICIGUAT (VERICIGUAT) — TORRENT PHARMACEUTICALS LTD | fda 2026-04-20 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA220313: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — AUROBINDO PHARMA | fda 2026-04-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA214120: ONUREG (AZACITIDINE) — BRISTOL | fda 2026-04-09 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA215833: PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — NOVARTIS | fda 2026-04-07 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA216718: SKYCLARYS (OMAVELOXOLONE) — BIOGEN US | fda 2026-04-07 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.58 | FDA BLA761055: DUPIXENT (DUPILUMAB) — REGENERON PHARMACEUTICALS | fda 2026-04-22 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA091541: LOSARTAN POTASSIUM (LOSARTAN POTASSIUM) — MICRO LABS | fda 2026-04-10 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA761328: BEYFORTUS (NIRSEVIMAB-ALIP) — ASTRAZENECA AB | fda 2026-04-07 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA207974: FINGOLIMOD HYDROCHLORIDE (FINGOLIMOD HYDROCHLORIDE) — ALEMBIC | fda 2026-04-24 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA212306: XPOVIO (SELINEXOR) — KARYOPHARM THERAPS | fda 2026-04-30 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA218093: FLECAINIDE ACETATE (FLECAINIDE ACETATE) — OMSAV PHARMA | fda 2026-04-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761304: VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — ARGENX BV | fda 2026-05-08 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA204345: CAPECITABINE (CAPECITABINE) — DR REDDYS | fda 2026-05-07 | 247_041 AI-powered drugs have 85% phase 1 success vs 52% traditional Peter Diamandis | Biotech/Longevity | 55% | |
| 0.58 | FDA ANDA204741: CAPECITABINE (CAPECITABINE) — AMNEAL PHARMS | fda 2026-05-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA203512: SPIRONOLACTONE (SPIRONOLACTONE) — ACCORD HLTHCARE | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA210689: FOSAPREPITANT DIMEGLUMINE (FOSAPREPITANT DIMEGLUMINE) — LUPIN | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA209224: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA BLA761452: IMMGOLIS (GOLIMUMAB-SLDI) — ACCORD BIOPHARMA INC. | fda 2026-05-15 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA091404: MEROPENEM (MEROPENEM) — ACS DOBFAR | fda 2026-05-20 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA216453: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ELITE LABS INC | fda 2026-05-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA211035: VERAPAMIL HYDROCHLORIDE (VERAPAMIL HYDROCHLORIDE) — SOMERSET | fda 2026-05-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA220499: ANDA220499 ((unspecified)) — ALEMBIC PHARMACEUTICALS LIMITED | fda 2026-05-13 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA BLA761394: DATROWAY (DATOPOTAMAB DERUXTECAN-DLNK) — DAIICHI SANKYO INC | fda 2026-05-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA211255: LINACLOTIDE (LINACLOTIDE) — ACTAVIS LABS FL INC | fda 2026-05-19 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA201749: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — SUN PHARM | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA076521: CARBIDOPA AND LEVODOPA (CARBIDOPA) — IMPAX LABS | fda 2026-05-28 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.58 | FDA NDA220442: NDA220442 ((unspecified)) — SHIONOGI INC | fda 2026-05-29 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA NDA210655: PERSERIS KIT (RISPERIDONE) — INDIVIOR | fda 2026-04-30 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA NDA210655: PERSERIS KIT (RISPERIDONE) — INDIVIOR | fda 2026-04-30 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.58 | FDA ANDA210671: MULTIPLE VITAMINS INJECTION PEDIATRIC (ASCORBIC ACID) — APOTEX | fda 2026-04-21 | 237_023 Baby AGI agents will need and develop an 'immune system' for prompt injection and cybersecurity threats in real time. Alex Wissner-Gross | AI | 41% | |
| 0.58 | FDA NDA206709: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA NDA020589: CHILDREN'S ADVIL-FLAVORED (IBUPROFEN) — HALEON US HOLDINGS | fda 2026-05-01 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.58 | FDA ANDA213165: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA215243: RAMELTEON (RAMELTEON) — MICRO LABS | fda 2026-04-15 | AI_031 AGI will be defined by its ability to autonomously formulate novel scientific hypotheses — effectively solving '100 years of biology' in a fraction of the historical time required, via continuous hypothesis-generation and experimental iteration. Demis Hassabis | Biotech/Longevity | 51% | |
| 0.58 | FDA ANDA217554: LENALIDOMIDE (LENALIDOMIDE) — DEVA HOLDING AS | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA213267: THALIDOMIDE (THALIDOMIDE) — NATCO | fda 2026-04-24 | 248_029 Regime change at the FDA is not beyond the realm of reason. Alex Wissner-Gross | Biotech/Longevity | 35% | |
| 0.58 | FDA NDA210793: NUPLAZID (PIMAVANSERIN TARTRATE) — ACADIA PHARMS INC | fda 2026-04-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA NDA207223: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA217957: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — UBI | fda 2026-05-06 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA216993: VANFLYTA (QUIZARTINIB DIHYDROCHLORIDE) — DAIICHI SANKYO INC | fda 2026-04-29 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA217477: ANDA217477 ((unspecified)) — HAINAN POLY PHARM. CO., LTD. | fda 2026-04-23 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA217239: TORSEMIDE (TORSEMIDE) — MICRO LABS | fda 2026-05-01 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA072735: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA021488: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA219494: SPIRONOLACTONE (SPIRONOLACTONE) — GRAVITI PHARMS | fda 2026-05-12 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA217761: SPIRONOLACTONE (SPIRONOLACTONE) — ANNORA PHARMA | fda 2026-05-12 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA761070: FASENRA (BENRALIZUMAB) — ASTRAZENECA AB | fda 2026-05-13 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA089534: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — SUN PHARM INDUSTRIES | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA210251: BIKTARVY (BICTEGRAVIR SODIUM) — GILEAD SCIENCES INC | fda 2026-05-21 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA NDA210251: BIKTARVY (BICTEGRAVIR SODIUM) — GILEAD SCIENCES INC | fda 2026-05-21 | SEM_026 Nvidia's next 'Rubin' product cycle is the most critical factor for semi industry in coming year — further integrates logic + HBM. Joseph Moore | Semis/Products | 71% | |
| 0.58 | FDA BLA761106: HERCEPTIN HYLECTA (TRASTUZUMAB AND HYALURONIDASE-OYSK) — GENENTECH INC | fda 2026-05-18 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA022561: MAVENCLAD (CLADRIBINE) — EMD SERONO INC | fda 2026-05-14 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA BLA761275: TYENNE (TOCILIZUMAB-AAZG) — FRESENIUS KABI USA | fda 2026-05-21 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.58 | FDA BLA761354: TOFIDENCE (TOCILIZUMAB-BAVI) — BIOGEN MA | fda 2026-05-22 | FUT_019 Global market rapidly accelerates bio-industrial circumvention of fractured supply chains 2026-2031: combination of Webb agentic LAMs overseeing vast bio-reactors powered by sub-cent-per-kWh solar energy creates highly-localized completely-autonomous i... Multi-Forecaster Synthesis | Biotech/Longevity | 31% | |
| 0.58 | FDA ANDA220499: ANDA220499 ((unspecified)) — ALEMBIC PHARMACEUTICALS LIMITED | fda 2026-05-13 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.58 | FDA BLA125166: SOLIRIS (ECULIZUMAB) — ALEXION PHARM | fda 2026-06-01 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA NDA018569: FUROSEMIDE (FUROSEMIDE) — EPIC PHARMA LLC | fda 2026-06-02 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA NDA206628: DEXMEDETOMIDINE HYDROCHLORIDE (DEXMEDETOMIDINE HYDROCHLORIDE) — HQ SPCLT PHARMA | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA211022: LENALIDOMIDE (LENALIDOMIDE) — APOTEX | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA210671: MULTIPLE VITAMINS INJECTION PEDIATRIC (ASCORBIC ACID) — APOTEX | fda 2026-04-21 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.58 | FDA NDA217779: RYTELO (IMETELSTAT SODIUM) — GERON | fda 2026-04-14 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA209348: LENALIDOMIDE (LENALIDOMIDE) — DR REDDYS | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA090169: LAMOTRIGINE (LAMOTRIGINE) — GLENMARK PHARMS LTD | fda 2026-04-10 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA220225: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ALEMBIC | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA217554: LENALIDOMIDE (LENALIDOMIDE) — DEVA HOLDING AS | fda 2026-04-27 | CMQ_037 Samsung will grow global HBM market share from 20% to 28% by securing majority of orders for Vera Rubin-exclusive HBM4. Morgan Stanley | Semis/Memory | 29% | |
| 0.58 | FDA NDA207223: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA090263: LEVETIRACETAM (LEVETIRACETAM) — CHARTWELL MOLECULAR | fda 2026-04-08 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA215759: LENALIDOMIDE (LENALIDOMIDE) — BIOCON PHARMA | fda 2026-04-27 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA NDA207318: NUPLAZID (PIMAVANSERIN TARTRATE) — ACADIA PHARMS INC | fda 2026-04-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA207694: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — LUPIN | fda 2026-04-30 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA213912: LENALIDOMIDE (LENALIDOMIDE) — MYLAN | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA211132: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — INGENUS PHARMS LLC | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA210236: POMALIDOMIDE (POMALIDOMIDE) — HETERO LABS LTD V | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA201446: FALLBACK SOLO (LEVONORGESTREL) — LUPIN | fda 2026-05-01 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA215276: NICOTINE POLACRILEX (NICOTINE POLACRILEX) — DR REDDYS LABS SA | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761147: ENNUMO (PEGFILGRASTIM-PCCG) — ACCORD BIOPHARMA INC. | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761045: ZIEXTENZO (PEGFILGRASTIM-BMEZ) — SANDOZ INC | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA200542: LORAZEPAM (LORAZEPAM) — RISING | fda 2026-05-15 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA214056: ONAPGO (APOMORPHINE HYDROCHLORIDE) — MDD US | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA218488: EVEROLIMUS (EVEROLIMUS) — APOTEX | fda 2026-05-12 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA077420: LAMOTRIGINE (LAMOTRIGINE) — RISING | fda 2026-05-15 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA090431: DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE) — RISING | fda 2026-04-09 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.58 | FDA ANDA211022: LENALIDOMIDE (LENALIDOMIDE) — APOTEX | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA219293: DANZITEN (NILOTINIB TARTRATE) — AZURITY | fda 2026-04-14 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA BLA761235: VABYSMO (FARICIMAB-SVOA) — GENENTECH INC | fda 2026-04-09 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.58 | FDA ANDA077686: DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE) — ACTAVIS LABS FL INC | fda 2026-04-09 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA018900: METRO I.V. IN PLASTIC CONTAINER (METRONIDAZOLE) — B BRAUN | fda 2026-04-23 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA220274: SODIUM ACETATE (SODIUM ACETATE) — EXTROVIS | fda 2026-04-17 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA210456: MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ASCORBIC ACID) — APOTEX | fda 2026-04-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA216213: LENALIDOMIDE (LENALIDOMIDE) — AMNEAL | fda 2026-04-27 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA212597: PIRFENIDONE (PIRFENIDONE) — AUROBINDO PHARMA | fda 2026-04-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761059: HADLIMA (ADALIMUMAB-BWWD) — SAMSUNG BIOEPIS CO LTD | fda 2026-04-29 | CMQ_037 Samsung will grow global HBM market share from 20% to 28% by securing majority of orders for Vera Rubin-exclusive HBM4. Morgan Stanley | Semis/Memory | 29% | |
| 0.58 | FDA ANDA211579: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — LUPIN | fda 2026-04-06 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA211583: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — TEVA PHARMS USA INC | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA213405: LENALIDOMIDE (LENALIDOMIDE) — TORRENT | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA NDA212122: BREZTRI AEROSPHERE (BUDESONIDE) — ASTRAZENECA AB | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA219941: MIRABEGRON (MIRABEGRON) — DEVA HOLDING AS | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA072733: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA072734: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — HIKMA | fda 2026-05-05 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA218316: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-05-05 | COD_TECH_001 A16/N2-class TSMC process availability materially supports 2027 AI accelerator ramps Codex Research Pack | Semis | 50% | |
| 0.58 | FDA NDA020515: ZOLADEX (GOSERELIN) — TERSERA | fda 2026-05-06 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA214618: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA BLA761100: ONTRUZANT (TRASTUZUMAB-DTTB) — SAMSUNG BIOEPIS CO LTD | fda 2026-04-15 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA021343: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA204345: CAPECITABINE (CAPECITABINE) — DR REDDYS | fda 2026-05-07 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA075471: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — MEITHEAL | fda 2026-05-06 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA BLA761195: VYVGART (EFGARTIGIMOD ALFA) — ARGENX BV | fda 2026-05-08 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA NDA219943: KOSELUGO (SELUMETINIB) — ASTRAZENECA | fda 2026-05-26 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA220041: TOPIRAMATE (TOPIRAMATE) — RICONPHARMA LLC | fda 2026-05-26 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA220444: PALBOCICLIB (PALBOCICLIB) — DR. REDDY'S LABORATORIES LIMITED | fda 2026-05-15 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA220068: FOSCARNET SODIUM (FOSCARNET SODIUM) — CAPLIN | fda 2026-05-13 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA077420: LAMOTRIGINE (LAMOTRIGINE) — RISING | fda 2026-05-15 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA220143: ANDA220143 ((unspecified)) — HETERO LABS LIMITED | fda 2026-05-22 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.58 | FDA ANDA220143: ANDA220143 ((unspecified)) — HETERO LABS LIMITED | fda 2026-05-22 | TK11 Autonomous Regulatory Block (Level 4 Halt) | — | 10% | |
| 0.58 | FDA NDA018569: FUROSEMIDE (FUROSEMIDE) — EPIC PHARMA LLC | fda 2026-06-02 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA219865: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — HETERO LABS LTD VI | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA219257: ANDA219257 ((unspecified)) — RENATA LIMITED | fda 2026-04-08 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA210671: MULTIPLE VITAMINS INJECTION PEDIATRIC (ASCORBIC ACID) — APOTEX | fda 2026-04-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA206709: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA219293: DANZITEN (NILOTINIB TARTRATE) — AZURITY | fda 2026-04-14 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA213165: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA NDA018900: METRO I.V. IN PLASTIC CONTAINER (METRONIDAZOLE) — B BRAUN | fda 2026-04-23 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.58 | FDA ANDA205254: ZOLEDRONIC ACID (ZOLEDRONIC ACID) — MYLAN LABS LTD | fda 2026-04-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA212212: BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE (BUDESONIDE) — TEVA PHARMS USA INC | fda 2026-04-23 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.58 | FDA BLA761451: SAPHNELO (ANIFROLIMAB-FNIA) — ASTRAZENECA AB | fda 2026-04-24 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA215833: PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) — NOVARTIS | fda 2026-04-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA214216: EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE (EMTRICITABINE) — MACLEODS PHARMS LTD | fda 2026-04-07 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA214216: EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE (EMTRICITABINE) — MACLEODS PHARMS LTD | fda 2026-04-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA217239: TORSEMIDE (TORSEMIDE) — MICRO LABS | fda 2026-05-01 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA090508: FINASTERIDE (FINASTERIDE) — SUN PHARM | fda 2026-04-30 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA200217: LORAZEPAM (LORAZEPAM) — RISING | fda 2026-05-04 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA NDA020578: ZOLADEX (GOSERELIN ACETATE) — TERSERA | fda 2026-05-06 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA020515: ZOLADEX (GOSERELIN) — TERSERA | fda 2026-05-06 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA761147: ENNUMO (PEGFILGRASTIM-PCCG) — ACCORD BIOPHARMA INC. | fda 2026-05-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA021379: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA022173: ZYPREXA RELPREVV (OLANZAPINE PAMOATE) — CHEPLAPHARM | fda 2026-05-07 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA208573: VENCLEXTA (VENETOCLAX) — ABBVIE | fda 2026-05-20 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA204994: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA214275: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA040191: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — STRIDES PHARMA INTL | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761111: NYVEPRIA (PEGFILGRASTIM-APGF) — HOSPIRA INC | fda 2026-05-21 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA062800: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ALMAJECT | fda 2026-05-28 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA219257: ANDA219257 ((unspecified)) — RENATA LIMITED | fda 2026-04-08 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA220274: SODIUM ACETATE (SODIUM ACETATE) — EXTROVIS | fda 2026-04-17 | 247_041 AI-powered drugs have 85% phase 1 success vs 52% traditional Peter Diamandis | Biotech/Longevity | 55% | |
| 0.58 | FDA BLA125514: KEYTRUDA (PEMBROLIZUMAB) — MERCK SHARP DOHME | fda 2026-05-12 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA215243: RAMELTEON (RAMELTEON) — MICRO LABS | fda 2026-04-15 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA218897: VALSARTAN (VALSARTAN) — LAURUS | fda 2026-04-21 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA220493: BUPIVACAINE HYDROCHLORIDE (BUPIVACAINE HYDROCHLORIDE) — ANTHEA PHARMA | fda 2026-04-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761451: SAPHNELO (ANIFROLIMAB-FNIA) — ASTRAZENECA AB | fda 2026-04-24 | COD_TECH_001 A16/N2-class TSMC process availability materially supports 2027 AI accelerator ramps Codex Research Pack | Semis | 50% | |
| 0.58 | FDA NDA020941: ABREVA (DOCOSANOL) — HALEON US HOLDINGS | fda 2026-04-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA212122: BREZTRI AEROSPHERE (BUDESONIDE) — ASTRAZENECA AB | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761328: BEYFORTUS (NIRSEVIMAB-ALIP) — ASTRAZENECA AB | fda 2026-04-07 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA210435: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA210449: CANAGLIFLOZIN (CANAGLIFLOZIN) — APOTEX | fda 2026-04-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA213912: LENALIDOMIDE (LENALIDOMIDE) — MYLAN | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA761291: TECVAYLI (TECLISTAMAB-CQYV) — JANSSEN BIOTECH | fda 2026-05-06 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA020578: ZOLADEX (GOSERELIN ACETATE) — TERSERA | fda 2026-05-06 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA071199: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — BARR | fda 2026-05-05 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA205402: PALIPERIDONE (PALIPERIDONE) — I3 PHARMS | fda 2026-05-07 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA219835: VEPPANU (VEPDEGESTRANT) — ARVINAS OPERATIONS | fda 2026-05-01 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA761347: TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — GENENTECH INC | fda 2026-05-15 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA220679: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — CENTAUR PHARMACEUTICALS PRIVATE LIMITED | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA217761: SPIRONOLACTONE (SPIRONOLACTONE) — ANNORA PHARMA | fda 2026-05-12 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA075471: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — MEITHEAL | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA204741: CAPECITABINE (CAPECITABINE) — AMNEAL PHARMS | fda 2026-05-07 | 247_041 AI-powered drugs have 85% phase 1 success vs 52% traditional Peter Diamandis | Biotech/Longevity | 55% | |
| 0.58 | FDA ANDA200880: ACETAZOLAMIDE SODIUM (ACETAZOLAMIDE SODIUM) — MYLAN ASI | fda 2026-05-07 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA204994: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA207812: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ZYDUS PHARMS | fda 2026-05-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA BLA761111: NYVEPRIA (PEGFILGRASTIM-APGF) — HOSPIRA INC | fda 2026-05-21 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA210040: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — AMNEAL PHARMS | fda 2026-05-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA210454: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — EUGIA PHARMA | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA217552: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ALEMBIC | fda 2026-05-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA081099: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — BARR | fda 2026-05-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA215356: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUROBINDO PHARMA LTD | fda 2026-06-03 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA215356: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUROBINDO PHARMA LTD | fda 2026-06-03 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA218407: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SUN PHARM INDS INC | fda 2026-06-03 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA091427: PAROXETINE HYDROCHLORIDE (PAROXETINE HYDROCHLORIDE) — AUROBINDO PHARMA USA | fda 2026-04-06 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA215575: ANDA215575 ((unspecified)) — QILU PHARM HAINAN | fda 2026-04-15 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA BLA761298: PAVBLU (AFLIBERCEPT-AYYH) — AMGEN INC | fda 2026-04-28 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA219509: PREDNISOLONE (PREDNISOLONE) — TP ANDA HOLDINGS | fda 2026-04-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA211491: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — SUN PHARM | fda 2026-05-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA071130: HALOPERIDOL (HALOPERIDOL) — AIPING PHARM INC | fda 2026-04-08 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA205756: METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE) — RISING | fda 2026-04-29 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA211545: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — ALKEM LABS LTD | fda 2026-04-06 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA NDA216718: SKYCLARYS (OMAVELOXOLONE) — BIOGEN US | fda 2026-04-07 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA216327: DILTIAZEM HYDROCHLORIDE (DILTIAZEM HYDROCHLORIDE) — SCIEGEN PHARMS | fda 2026-04-10 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA213405: LENALIDOMIDE (LENALIDOMIDE) — TORRENT | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA220314: SEMAGLUTIDE (SEMAGLUTIDE) — APOTEX INC | fda 2026-04-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA060469: TETRACYCLINE HYDROCHLORIDE (TETRACYCLINE HYDROCHLORIDE) — IMPAX LABS | fda 2026-04-17 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA205519: ATORVASTATIN CALCIUM (ATORVASTATIN CALCIUM) — SCIEGEN PHARMS | fda 2026-04-28 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA218558: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — MICRO LABS | fda 2026-05-07 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA207740: OMEPRAZOLE (OMEPRAZOLE) — DR REDDYS | fda 2026-04-29 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA207740: OMEPRAZOLE (OMEPRAZOLE) — DR REDDYS | fda 2026-04-29 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA218148: ATROPINE SULFATE (ATROPINE SULFATE) — MANKIND PHARMA | fda 2026-05-07 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA BLA761195: VYVGART (EFGARTIGIMOD ALFA) — ARGENX BV | fda 2026-05-08 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA BLA125554: OPDIVO (NIVOLUMAB) — BRISTOL MYERS SQUIBB | fda 2026-05-12 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA BLA761468: HEPCLUDEX (BULEVIRTIDE-GMOD) — GILEAD SCIENCES INC | fda 2026-05-22 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA077420: LAMOTRIGINE (LAMOTRIGINE) — RISING | fda 2026-05-15 | 247_041 AI-powered drugs have 85% phase 1 success vs 52% traditional Peter Diamandis | Biotech/Longevity | 55% | |
| 0.58 | FDA ANDA220043: VORICONAZOLE (VORICONAZOLE) — HAINAN POLY PHARM | fda 2026-05-29 | CMQ_035 HBM4 16-layer stack design (required for Vera Rubin) places unprecedented yield and capacity strain on global memory fabrication facilities. Jensen Huang / Morgan Stanley | Semis/Memory | 68% | |
| 0.58 | FDA ANDA077120: CARBIDOPA AND LEVODOPA (CARBIDOPA) — APOTEX INC | fda 2026-05-28 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.58 | FDA BLA761069: IMFINZI (DURVALUMAB) — ASTRAZENECA UK LTD | fda 2026-05-28 | 247_029 OpenAI Foundation's cure for Alzheimer's could spawn a trillion-dollar pharma company Alex Wissner-Gross | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLC | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA218405: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (SITAGLIPTIN, METFORMIN HYDROCHLORIDE) — MANKIND PHARMA LTD | fda 2026-05-21 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA220442: NDA220442 ((unspecified)) — SHIONOGI INC | fda 2026-05-29 | IND_020 Massive 'rerating' of Biotech industry — by 2026, generative biology achieves its 'De Novo' moment where an AI-designed drug candidate triggers multi-billion-dollar partnerships; AI expands Total Addressable Market (TAM) of gene editing by 100x, moving... Morgan Stanley | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA220482: NDA220482 ((unspecified)) — HAISCO PHARMACEUTICAL GROUP CO LTD | fda 2026-05-29 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA BLA761139: ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — DAIICHI SANKYO | fda 2026-05-15 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA BLA761139: ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — DAIICHI SANKYO | fda 2026-05-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA021366: CRESTOR (ROSUVASTATIN CALCIUM) — ASTRAZENECA | fda 2026-04-29 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA213093: ANDA213093 ((unspecified)) — QILU PHARM CO LTD | fda 2026-04-29 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA076781: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — HIKMA FARMACEUTICA | fda 2026-04-08 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA076781: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — HIKMA FARMACEUTICA | fda 2026-04-08 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA220147: TOLVAPTAN (TOLVAPTAN) — ALKEM LABS LTD | fda 2026-04-21 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA207110: BOSENTAN (BOSENTAN) — WATSON LABS INC | fda 2026-04-14 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA213165: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA207223: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.58 | FDA ANDA203364: MESNA (MESNA) — RISING | fda 2026-04-09 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA071130: HALOPERIDOL (HALOPERIDOL) — AIPING PHARM INC | fda 2026-04-08 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.58 | FDA NDA209500: CAPLYTA (LUMATEPERONE TOSYLATE) — INTRA-CELLULAR | fda 2026-04-24 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA091655: ESCITALOPRAM OXALATE (ESCITALOPRAM OXALATE) — MICRO LABS | fda 2026-04-22 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.58 | FDA ANDA213405: LENALIDOMIDE (LENALIDOMIDE) — TORRENT | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA210435: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA204072: METHYLPREDNISOLONE (METHYLPREDNISOLONE) — TIANJIN TIANYAO | fda 2026-04-10 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA217477: ANDA217477 ((unspecified)) — HAINAN POLY PHARM. CO., LTD. | fda 2026-04-23 | FUT_019 Global market rapidly accelerates bio-industrial circumvention of fractured supply chains 2026-2031: combination of Webb agentic LAMs overseeing vast bio-reactors powered by sub-cent-per-kWh solar energy creates highly-localized completely-autonomous i... Multi-Forecaster Synthesis | Biotech/Longevity | 31% | |
| 0.58 | FDA ANDA220398: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — MANKIND PHARMA | fda 2026-04-16 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA219494: SPIRONOLACTONE (SPIRONOLACTONE) — GRAVITI PHARMS | fda 2026-05-12 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA021731: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA215256: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-05-05 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA NDA215256: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-05-05 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA218662: UBROGEPANT (UBROGEPANT) — ZYDUS PHARMACEUTICALS (USA) INC. | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA218662: UBROGEPANT (UBROGEPANT) — ZYDUS PHARMACEUTICALS (USA) INC. | fda 2026-05-14 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA078480: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — APOTEX | fda 2026-05-20 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA217497: TRETINOIN (TRETINOIN) — AMNEAL | fda 2026-05-14 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA218488: EVEROLIMUS (EVEROLIMUS) — APOTEX | fda 2026-05-12 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.58 | FDA NDA213756: KOSELUGO (SELUMETINIB SULFATE) — ASTRAZENECA | fda 2026-05-26 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA062801: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ALMAJECT | fda 2026-05-28 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA076521: CARBIDOPA AND LEVODOPA (CARBIDOPA) — IMPAX LABS | fda 2026-05-28 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA209091: QTERN (DAPAGLIFLOZIN) — ASTRAZENECA AB | fda 2026-06-03 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLC | fda 2026-06-03 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.58 | FDA ANDA215332: OXCARBAZEPINE (OXCARBAZEPINE) — AUCTA | fda 2026-06-02 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.58 | FDA ANDA207760: BOSENTAN (BOSENTAN) — ZYDUS PHARMS | fda 2026-04-14 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA210275: POMALIDOMIDE (POMALIDOMIDE) — MYLAN | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA215575: ANDA215575 ((unspecified)) — QILU PHARM HAINAN | fda 2026-04-15 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA220033: ELTROMBOPAG OLAMINE (ELTROMBOPAG OLAMINE) — ZENARA | fda 2026-04-08 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA125261: STELARA (USTEKINUMAB) — CENTOCOR ORTHO BIOTECH INC | fda 2026-04-15 | FUT_019 Global market rapidly accelerates bio-industrial circumvention of fractured supply chains 2026-2031: combination of Webb agentic LAMs overseeing vast bio-reactors powered by sub-cent-per-kWh solar energy creates highly-localized completely-autonomous i... Multi-Forecaster Synthesis | Biotech/Longevity | 31% | |
| 0.58 | FDA BLA125261: STELARA (USTEKINUMAB) — CENTOCOR ORTHO BIOTECH INC | fda 2026-04-15 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA073484: VALPROIC ACID (VALPROIC ACID) — BIONPHARMA | fda 2026-04-08 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA BLA125409: PERJETA (PERTUZUMAB) — GENENTECH | fda 2026-04-23 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA214398: LENALIDOMIDE (LENALIDOMIDE) — LUPIN | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA213267: THALIDOMIDE (THALIDOMIDE) — NATCO | fda 2026-04-24 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.58 | FDA ANDA078956: LAMOTRIGINE (LAMOTRIGINE) — AUROBINDO PHARMA | fda 2026-04-09 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA071130: HALOPERIDOL (HALOPERIDOL) — AIPING PHARM INC | fda 2026-04-08 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA NDA220837: EVDI (TRABECTEDIN) — APOTEX | fda 2026-05-01 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.58 | FDA ANDA211846: LENALIDOMIDE (LENALIDOMIDE) — SUN PHARM | fda 2026-04-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA BLA761467: KEYTRUDA QLEX (PEMBROLIZUMAB) — MERCK SHARP DOHME | fda 2026-05-12 | SEM_029 Blackwell RTX PRO 5000 (72GB) engineered with 50% memory boost over previous generation — deliberate architectural concession for larger AI training. Nvidia | Semis/Products | 79% | |
| 0.58 | FDA ANDA218509: IVERMECTIN (IVERMECTIN) — AJANTA PHARMA LTD | fda 2026-04-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA083158: LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% (LIDOCAINE HYDROCHLORIDE) — HOSPIRA | fda 2026-04-10 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA ANDA206387: ALENDRONATE SODIUM (ALENDRONATE SODIUM) — IPCA LABS LTD | fda 2026-04-15 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA220326: VILOXAZINE HYDROCHLORIDE (VILOXAZINE HYDROCHLORIDE) — APPCO PHARMA LLC | fda 2026-04-28 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA210435: LENALIDOMIDE (LENALIDOMIDE) — CIPLA | fda 2026-04-27 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA078945: ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (ONDANSETRON HYDROCHLORIDE) — AVET LIFESCIENCES | fda 2026-05-01 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA019010: LUPRON (LEUPROLIDE ACETATE) — ABBVIE ENDOCRINE INC | fda 2026-05-06 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA204741: CAPECITABINE (CAPECITABINE) — AMNEAL PHARMS | fda 2026-05-07 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA200880: ACETAZOLAMIDE SODIUM (ACETAZOLAMIDE SODIUM) — MYLAN ASI | fda 2026-05-07 | COD_TECH_001 A16/N2-class TSMC process availability materially supports 2027 AI accelerator ramps Codex Research Pack | Semis | 50% | |
| 0.58 | FDA NDA022173: ZYPREXA RELPREVV (OLANZAPINE PAMOATE) — CHEPLAPHARM | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA019414: CARDIOGEN-82 (RUBIDIUM CHLORIDE RB-82) — BRACCO | fda 2026-05-13 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.58 | FDA ANDA219189: GALLIUM GA-68 GOZETOTIDE (GALLIUM GA-68 GOZETOTIDE) — IONETIX | fda 2026-05-14 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA NDA214275: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA040191: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — STRIDES PHARMA INTL | fda 2026-05-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA ANDA220299: ISOPROTERENOL HYDROCHLORIDE (ISOPROTERENOL HYDROCHLORIDE) — ASPIRO | fda 2026-05-18 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA NDA204114: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — NOVARTIS | fda 2026-05-07 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA NDA220711: BEQALZI (SONROTOCLAX) — BEONE MEDICINES USA | fda 2026-05-13 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA207717: OXCARBAZEPINE (OXCARBAZEPINE) — RUBICON RESEARCH | fda 2026-05-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA207947: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | 240_056 Anthropic enterprise market share to continue growing (went from 40% to 73% in 3 months) Peter Diamandis | AI | 54% | |
| 0.58 | FDA NDA022180: FERAHEME (FERUMOXYTOL) — AZURITY | fda 2026-05-27 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA NDA202811: LINZESS (LINACLOTIDE) — ABBVIE | fda 2026-05-21 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA062800: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ALMAJECT | fda 2026-05-28 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA BLA761108: ULTOMIRIS (RAVULIZUMAB-CWVZ) — ALEXION PHARM | fda 2026-06-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.58 | FDA BLA761108: ULTOMIRIS (RAVULIZUMAB-CWVZ) — ALEXION PHARM | fda 2026-06-01 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.58 | FDA ANDA062943: CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE) — ALMAJECT | fda 2026-05-28 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA ANDA215332: OXCARBAZEPINE (OXCARBAZEPINE) — AUCTA | fda 2026-06-02 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.58 | FDA NDA202293: FARXIGA (DAPAGLIFLOZIN) — ASTRAZENECA AB | fda 2026-06-03 | SEM_022 FP4 / ternary-weight architectures decouple AI capability from raw transistor density — embargoed nations maintain competitive development. Dave Blundin | AI/Architecture | 65% | |
| 0.58 | FDA ANDA218405: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (SITAGLIPTIN, METFORMIN HYDROCHLORIDE) — MANKIND PHARMA LTD | fda 2026-05-21 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.58 | FDA NDA201848: HEPZATO (MELPHALAN HYDROCHLORIDE) — DELCATH SYSTEMS INC | fda 2026-05-28 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA090431: DOXYCYCLINE HYCLATE (DOXYCYCLINE HYCLATE) — RISING | fda 2026-04-09 | 245_010 Breaking will pursue a human-body microplastic solution (supplement) in addition to environmental plastic degradation Ben Lamm | Biotech/Longevity | 41% | |
| 0.57 | FDA ANDA078257: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — ONESOURCE SPECIALTY | fda 2026-04-15 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA073484: VALPROIC ACID (VALPROIC ACID) — BIONPHARMA | fda 2026-04-08 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA220225: METHOTREXATE SODIUM (METHOTREXATE SODIUM) — ALEMBIC | fda 2026-04-15 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA ANDA211523: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — AIZANT | fda 2026-04-06 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA NDA209500: CAPLYTA (LUMATEPERONE TOSYLATE) — INTRA-CELLULAR | fda 2026-04-24 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.57 | FDA BLA761044: STELARA (USTEKINUMAB) — JANSSEN BIOTECH | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA219072: CARBAMAZEPINE (CARBAMAZEPINE) — YICHANG HUMANWELL | fda 2026-04-17 | 248_029 Regime change at the FDA is not beyond the realm of reason. Alex Wissner-Gross | Biotech/Longevity | 35% | |
| 0.57 | FDA ANDA207694: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — LUPIN | fda 2026-04-30 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA ANDA210164: POMALIDOMIDE (POMALIDOMIDE) — APOTEX | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA NDA218316: WEGOVY (SEMAGLUTIDE) — NOVO | fda 2026-05-05 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.57 | FDA NDA219804: DOLUTEGRAVIR, LAMIVUDINE and TENOFOVIR DISOPROXIL FUMARATE (DOLUTEGRAVIR) — LACHMAN CONSULTANT SERVICES , INC. | fda 2026-05-07 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.57 | FDA ANDA079204: LAMOTRIGINE (LAMOTRIGINE) — TARO | fda 2026-05-06 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA ANDA217432: FAMOTIDINE (FAMOTIDINE) — LUPIN | fda 2026-05-12 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.57 | FDA ANDA218662: UBROGEPANT (UBROGEPANT) — ZYDUS PHARMACEUTICALS (USA) INC. | fda 2026-05-14 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA203708: OLANZAPINE (OLANZAPINE) — AUROBINDO PHARMA LTD | fda 2026-05-26 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.57 | FDA ANDA212975: IMATINIB MESYLATE (IMATINIB MESYLATE) — HETERO LABS LTD V | fda 2026-05-22 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA NDA217186: CREXONT (CARBIDOPA) — IMPAX | fda 2026-05-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA NDA212102: FINTEPLA (FENFLURAMINE HYDROCHLORIDE) — UCB INC | fda 2026-05-22 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA NDA214018: NULIBRY (FOSDENOPTERIN HYDROBROMIDE) — SENTYNL THERAPS INC | fda 2026-05-26 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA ANDA076089: CIPROFLOXACIN HYDROCHLORIDE (CIPROFLOXACIN HYDROCHLORIDE) — IVAX SUB TEVA PHARMS | fda 2026-05-19 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA220137: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SOMERSET THERAPS LLC | fda 2026-06-03 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA BLA761139: ENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — DAIICHI SANKYO | fda 2026-05-15 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.57 | FDA ANDA207037: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — ALKEM LABS LTD | fda 2026-04-23 | SEM_014 Nvidia's Arizona-based TSMC factory successfully fabricated cutting-edge semiconductors on US soil for first time in decades (October 2025). Jensen Huang | Manufacturing | 86% | |
| 0.57 | FDA ANDA219973: PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM) — SHUANGCHENG | fda 2026-04-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA216068: ENZALUTAMIDE (ENZALUTAMIDE) — SANDOZ | fda 2026-04-20 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA220313: GLYCEROL PHENYLBUTYRATE (GLYCEROL PHENYLBUTYRATE) — AUROBINDO PHARMA | fda 2026-04-15 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.57 | FDA ANDA219408: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — SCIEGEN PHARMACEUTICALS INC | fda 2026-04-30 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA210154: LENALIDOMIDE (LENALIDOMIDE) — ZYDUS PHARMS | fda 2026-04-27 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA ANDA205756: METHYLPHENIDATE HYDROCHLORIDE (METHYLPHENIDATE HYDROCHLORIDE) — RISING | fda 2026-04-29 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.57 | FDA ANDA040719: METHYLPREDNISOLONE ACETATE (METHYLPREDNISOLONE ACETATE) — SANDOZ | fda 2026-04-10 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.57 | FDA NDA215430: AUVELITY (BUPROPION HYDROCHLORIDE) — AXSOME | fda 2026-04-30 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA BLA761183: TZIELD (TEPLIZUMAB-MZWV) — PROVENTION BIO INC | fda 2026-04-20 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.57 | FDA BLA761183: TZIELD (TEPLIZUMAB-MZWV) — PROVENTION BIO INC | fda 2026-04-20 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA NDA205422: REXULTI (BREXPIPRAZOLE) — OTSUKA | fda 2026-04-30 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA NDA205422: REXULTI (BREXPIPRAZOLE) — OTSUKA | fda 2026-04-30 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA NDA021343: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA079204: LAMOTRIGINE (LAMOTRIGINE) — TARO | fda 2026-05-06 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.57 | FDA ANDA200880: ACETAZOLAMIDE SODIUM (ACETAZOLAMIDE SODIUM) — MYLAN ASI | fda 2026-05-07 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA NDA019414: CARDIOGEN-82 (RUBIDIUM CHLORIDE RB-82) — BRACCO | fda 2026-05-13 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA ANDA204994: LACOSAMIDE (LACOSAMIDE) — AUROBINDO PHARMA LTD | fda 2026-05-22 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA NDA212035: ARGATROBAN IN SODIUM CHLORIDE (ARGATROBAN) — ACCORD HLTHCARE | fda 2026-05-21 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA NDA219943: KOSELUGO (SELUMETINIB) — ASTRAZENECA | fda 2026-05-26 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA203708: OLANZAPINE (OLANZAPINE) — AUROBINDO PHARMA LTD | fda 2026-05-26 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA NDA213756: KOSELUGO (SELUMETINIB SULFATE) — ASTRAZENECA | fda 2026-05-26 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA210215: AMANTADINE HYDROCHLORIDE (AMANTADINE HYDROCHLORIDE) — POM PHARMA | fda 2026-05-13 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA NDA219423: WIDAPLIK (AMLODIPINE BESYLATE) — AZURITY | fda 2026-05-28 | SEM_020 Nvidia preemptively reserved 800,000-850,000 TSMC wafers for 2026 — 8x SMIC's entire advanced-process capacity. Nvidia (All-In Podcast analysis) | Semis | 74% | |
| 0.57 | FDA NDA202811: LINZESS (LINACLOTIDE) — ABBVIE | fda 2026-05-21 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.57 | FDA ANDA218407: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — SUN PHARM INDS INC | fda 2026-06-03 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA ANDA091427: PAROXETINE HYDROCHLORIDE (PAROXETINE HYDROCHLORIDE) — AUROBINDO PHARMA USA | fda 2026-04-06 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA BLA125261: STELARA (USTEKINUMAB) — CENTOCOR ORTHO BIOTECH INC | fda 2026-04-15 | SEM_028 Main characters for semi institutional portfolios: Nvidia, Broadcom, and high-growth connectivity firms like Astera Labs. Joseph Moore | Capital Markets | 61% | |
| 0.57 | FDA NDA206709: DIACOMIT (STIRIPENTOL) — BIOCODEX SA | fda 2026-04-15 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.57 | FDA ANDA218740: CETRORELIX ACETATE (CETRORELIX ACETATE) — HUMANWELL | fda 2026-04-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA NDA217369: ZURZUVAE (ZURANOLONE) — BIOGEN INC | fda 2026-04-20 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.57 | FDA ANDA216068: ENZALUTAMIDE (ENZALUTAMIDE) — SANDOZ | fda 2026-04-20 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.57 | FDA BLA761298: PAVBLU (AFLIBERCEPT-AYYH) — AMGEN INC | fda 2026-04-28 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.57 | FDA NDA020310: NIZORAL ANTI-DANDRUFF (KETOCONAZOLE) — KRAMER | fda 2026-04-30 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA ANDA210456: MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ASCORBIC ACID) — APOTEX | fda 2026-04-21 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.57 | FDA NDA218390: INGREZZA SPRINKLE (VALBENAZINE TOSYLATE) — NEUROCRINE | fda 2026-04-08 | 245_009 Breaking plastic-degradation technology could become a supplement that breaks microplastics in the gut before absorption Peter Diamandis | Biotech/Longevity | 45% | |
| 0.57 | FDA ANDA210111: POMALIDOMIDE (POMALIDOMIDE) — BRECKENRIDGE | fda 2026-04-27 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA ANDA215336: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — AMNEAL | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA218417: DEXTROMETHORPHAN POLISTIREX (DEXTROMETHORPHAN POLISTIREX) — AUROBINDO PHARMA LTD | fda 2026-04-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA ANDA206863: DALFAMPRIDINE (DALFAMPRIDINE) — ACCORD HLTHCARE | fda 2026-04-20 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA210154: LENALIDOMIDE (LENALIDOMIDE) — ZYDUS PHARMS | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.57 | FDA ANDA217957: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — UBI | fda 2026-05-06 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.57 | FDA ANDA091655: ESCITALOPRAM OXALATE (ESCITALOPRAM OXALATE) — MICRO LABS | fda 2026-04-22 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 87% | |
| 0.57 | FDA ANDA219755: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) — INVENTIA HEALTHCARE LIMITED | fda 2026-04-09 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA BLA761340: EPYSQLI (ECULIZUMAB-AAGH) — SAMSUNG BIOEPIS CO LTD | fda 2026-04-28 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.57 | FDA BLA761349: COSENTYX (SECUKINUMAB) — NOVARTIS PHARMS CORP | fda 2026-04-17 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA213912: LENALIDOMIDE (LENALIDOMIDE) — MYLAN | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA218840: CALCIUM GLUCONATE (CALCIUM GLUCONATE) — CAPLIN | fda 2026-05-04 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA078982: LAMOTRIGINE (LAMOTRIGINE) — GRANULES | fda 2026-04-30 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.57 | FDA NDA016730: DEXTROSE 5% IN PLASTIC CONTAINER (DEXTROSE) — B BRAUN | fda 2026-05-12 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA BLA761285: WEZLANA (USTEKINUMAB-AUUB) — AMGEN INC | fda 2026-05-12 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA BLA761304: VYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — ARGENX BV | fda 2026-05-08 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA NDA204819: ADEMPAS (RIOCIGUAT) — BAYER HLTHCARE | fda 2026-05-08 | IND_012 NVIDIA BioNeMo platform + Evo 2 model fundamentally compresses a century of biology into a decade — Evo 2 achieves 90% accuracy in BRCA1 predictions; AI models will seamlessly transition generated biological designs into practical, synthesized clinical... Jensen Huang | Biotech/Longevity | 68% | |
| 0.57 | FDA BLA761381: OPDIVO QVANTIG (NIVOLUMAB) — BRISTOL-MYERS SQUIBB | fda 2026-05-12 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA NDA021731: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA077663: SERTRALINE HYDROCHLORIDE (SERTRALINE HYDROCHLORIDE) — HERITAGE PHARMA AVET | fda 2026-05-07 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.57 | FDA BLA761468: HEPCLUDEX (BULEVIRTIDE-GMOD) — GILEAD SCIENCES INC | fda 2026-05-22 | FUT_019 Global market rapidly accelerates bio-industrial circumvention of fractured supply chains 2026-2031: combination of Webb agentic LAMs overseeing vast bio-reactors powered by sub-cent-per-kWh solar energy creates highly-localized completely-autonomous i... Multi-Forecaster Synthesis | Biotech/Longevity | 31% | |
| 0.57 | FDA BLA103792: HERCEPTIN (TRASTUZUMAB) — GENENTECH | fda 2026-05-18 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA217497: TRETINOIN (TRETINOIN) — AMNEAL | fda 2026-05-14 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA215411: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (SITAGLIPTIN, METFORMIN HYDROCHLORIDE) — INVENTIA HEALTHCARE LIMITED | fda 2026-05-07 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.57 | FDA ANDA220673: CLOMIPHENE CITRATE (CLOMIPHENE CITRATE) — ASCENT PHARMS INC | fda 2026-05-15 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA ANDA211255: LINACLOTIDE (LINACLOTIDE) — ACTAVIS LABS FL INC | fda 2026-05-19 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.57 | FDA NDA217379: NDA217379 ((unspecified)) — FLEX PHARMA, LLC | fda 2026-05-29 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA218405: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (SITAGLIPTIN, METFORMIN HYDROCHLORIDE) — MANKIND PHARMA LTD | fda 2026-05-21 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA ANDA079099: LAMOTRIGINE (LAMOTRIGINE) — GLENMARK PHARMS LTD | fda 2026-04-17 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.57 | FDA NDA022063: MYDAYIS (AMPHETAMINE ASPARTATE) — TAKEDA PHARMS USA | fda 2026-04-23 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA219897: PIMOZIDE (PIMOZIDE) — NOVITIUM PHARMA | fda 2026-04-13 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA213093: ANDA213093 ((unspecified)) — QILU PHARM CO LTD | fda 2026-04-29 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.57 | FDA ANDA213093: ANDA213093 ((unspecified)) — QILU PHARM CO LTD | fda 2026-04-29 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA206252: QUETIAPINE FUMARATE (QUETIAPINE FUMARATE) — ACCORD HLTHCARE | fda 2026-04-22 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA215575: ANDA215575 ((unspecified)) — QILU PHARM HAINAN | fda 2026-04-15 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.57 | FDA ANDA217772: FOSFOMYCIN TROMETHAMINE (FOSFOMYCIN TROMETHAMINE) — AUCTA | fda 2026-04-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA220221: VERICIGUAT (VERICIGUAT) — TORRENT PHARMACEUTICALS LTD | fda 2026-04-20 | 248_030 FDA will be first government agency forced to get out of the way; government must accelerate regulation speed thousands of times. Dave Blundin | Geopolitics | 50% | |
| 0.57 | FDA NDA018900: METRO I.V. IN PLASTIC CONTAINER (METRONIDAZOLE) — B BRAUN | fda 2026-04-23 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA ANDA220264: VERICIGUAT (VERICIGUAT) — CHANGZHOU PHARMACEUTICAL FACTORY | fda 2026-04-08 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA220269: NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) (NITROFURANTOIN) — CREEKWOOD PHARMS | fda 2026-04-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA NDA204026: POMALYST (POMALIDOMIDE) — BRISTOL | fda 2026-04-27 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA217554: LENALIDOMIDE (LENALIDOMIDE) — DEVA HOLDING AS | fda 2026-04-27 | CMQ_035 HBM4 16-layer stack design (required for Vera Rubin) places unprecedented yield and capacity strain on global memory fabrication facilities. Jensen Huang / Morgan Stanley | Semis/Memory | 68% | |
| 0.57 | FDA ANDA210154: LENALIDOMIDE (LENALIDOMIDE) — ZYDUS PHARMS | fda 2026-04-27 | SEM_026 Nvidia's next 'Rubin' product cycle is the most critical factor for semi industry in coming year — further integrates logic + HBM. Joseph Moore | Semis/Products | 71% | |
| 0.57 | FDA NDA214120: ONUREG (AZACITIDINE) — BRISTOL | fda 2026-04-09 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.57 | FDA ANDA219593: PREGABALIN (PREGABALIN) — UNICHEM | fda 2026-04-30 | CMQ_009 Altman's claim of doctor-level AI diagnostic capability within 2-3 years is 'pure nonsense' — fails to account for medical communication, diagnostic uncertainty, and ethical complexity. Demis Hassabis | AI | 60% | |
| 0.57 | FDA BLA761044: STELARA (USTEKINUMAB) — JANSSEN BIOTECH | fda 2026-04-15 | INF_027 AI infrastructure applied to structural biology will compress drug-development timelines from approximately a decade to weeks — potentially eradicating many major diseases within 10 years. Requires localized high-speed InfiniBand networking inside the DC. Demis Hassabis | Biotech/Longevity | 38% | |
| 0.57 | FDA BLA761467: KEYTRUDA QLEX (PEMBROLIZUMAB) — MERCK SHARP DOHME | fda 2026-05-12 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA BLA761467: KEYTRUDA QLEX (PEMBROLIZUMAB) — MERCK SHARP DOHME | fda 2026-05-12 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA ANDA060469: TETRACYCLINE HYDROCHLORIDE (TETRACYCLINE HYDROCHLORIDE) — IMPAX LABS | fda 2026-04-17 | 245_010 Breaking will pursue a human-body microplastic solution (supplement) in addition to environmental plastic degradation Ben Lamm | Biotech/Longevity | 41% | |
| 0.57 | FDA BLA761053: OCREVUS (OCRELIZUMAB) — GENENTECH INC | fda 2026-05-08 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA BLA761053: OCREVUS (OCRELIZUMAB) — GENENTECH INC | fda 2026-05-08 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA ANDA071198: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — BARR | fda 2026-05-05 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA BLA761032: SILIQ (BRODALUMAB) — VALEANT LUXEMBOURG | fda 2026-05-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA BLA761032: SILIQ (BRODALUMAB) — VALEANT LUXEMBOURG | fda 2026-05-07 | FUT_019 Global market rapidly accelerates bio-industrial circumvention of fractured supply chains 2026-2031: combination of Webb agentic LAMs overseeing vast bio-reactors powered by sub-cent-per-kWh solar energy creates highly-localized completely-autonomous i... Multi-Forecaster Synthesis | Biotech/Longevity | 31% | |
| 0.57 | FDA ANDA215826: LEUPROLIDE ACETATE (LEUPROLIDE ACETATE) — ZYDUS PHARMS | fda 2026-05-06 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA NDA205422: REXULTI (BREXPIPRAZOLE) — OTSUKA | fda 2026-04-30 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.57 | FDA NDA022433: BRILINTA (TICAGRELOR) — ASTRAZENECA | fda 2026-05-07 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.57 | FDA ANDA218148: ATROPINE SULFATE (ATROPINE SULFATE) — MANKIND PHARMA | fda 2026-05-07 | 240_056 Anthropic enterprise market share to continue growing (went from 40% to 73% in 3 months) Peter Diamandis | AI | 54% | |
| 0.57 | FDA ANDA215260: SUGAMMADEX (SUGAMMADEX) — TAMARANG SA | fda 2026-05-12 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.57 | FDA BLA761347: TECENTRIQ HYBREZA (ATEZOLIZUMAB AND HYALURONIDASE-TQJS) — GENENTECH INC | fda 2026-05-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA NDA021731: ELIGARD KIT (LEUPROLIDE ACETATE) — TOLMAR | fda 2026-05-06 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.57 | FDA ANDA212068: VASOPRESSIN (VASOPRESSIN) — SANDOZ | fda 2026-05-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 36% | |
| 0.57 | FDA ANDA210689: FOSAPREPITANT DIMEGLUMINE (FOSAPREPITANT DIMEGLUMINE) — LUPIN | fda 2026-04-30 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% | |
| 0.57 | FDA ANDA212682: NEBIVOLOL HYDROCHLORIDE (NEBIVOLOL HYDROCHLORIDE) — PRINSTON INC | fda 2026-05-20 | SEM_026 Nvidia's next 'Rubin' product cycle is the most critical factor for semi industry in coming year — further integrates logic + HBM. Joseph Moore | Semis/Products | 71% | |
| 0.57 | FDA NDA022561: MAVENCLAD (CLADRIBINE) — EMD SERONO INC | fda 2026-05-14 | CMQ_010 True AGI requires genuine scientific-discovery capabilities (AlphaFold-class breakthroughs) — brute-force LLM scaling alone is insufficient. Demis Hassabis | AI | 49% |